Fermenta Biotech Peer Comparison

NSE: FERMENTA | BSE: 506414

₹479.30

₹10.90 (2.33%)

As on 28-Sep-2026IST

Market cap

₹1,405 Cr

Revenue (TTM)

₹511 Cr

P/E Ratio

23.2

P/B Ratio

3.4

Div. Yield

0.8 %

Edit

	Fermenta Biotech	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Market cap (₹ Cr)	1,405	21,684	20,012	18,151	17,148
Revenue (₹ Cr)	511	2,287	1,682	2,570	3,230
Net Profit (₹ Cr)	58.19	678.07	273.51	735.15	666.92
Net Margin (%)	11.00	28.10	16.19	26.88	20.60
RoE (%)	13.91	19.73	11.15	19.16	18.75
Price to Earnings	23.23	32.59	67.31	24.69	26.63
Price-To-Book	3.40	5.90	7.45	4.12	4.25

Income Statement (₹ Cr)

	Fermenta Biotech	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Operating Revenue	510.99	2,287.33	1,682.47	2,569.77	3,229.67
Total Income	528.98	2,413.29	1,689.83	2,735.39	3,237.12
Total Expenditure	421.33	1,490.75	1,203.91	1,628.14	2,090.06
EBITDA	89.66	796.58	478.55	941.63	1,139.61
Depreciation	21.08	78.10	126.01	57.58	281.06
EBIT	68.58	718.48	352.55	884.05	858.55
Interest	10.97	0.88	52.11	7.69	190.64
Other Income	17.99	125.96	7.37	165.62	7.45
Exceptional Items	6.88	0.00	12.16	-49.16	-17.24
Profit before Tax	82.47	843.56	319.96	992.82	658.12
Provision for Tax	24.28	165.49	46.45	257.67	-8.80
Profit after Tax	58.19	678.07	273.51	735.15	666.92

	Fermenta Biotech	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Shareholder's Funds	406.21	3,586.42	2,591.20	4,202.90	3,902.67
Minority Interest	2.30	-12.71	0.00	0.00	-21.81
Non-Current Liabilities	38.62	28.74	266.35	91.50	1,392.75
Current Liabilities	208.78	385.94	848.06	627.48	2,077.10
Total Liabilities	647.94	4,037.51	3,705.61	4,921.88	7,246.72

	Fermenta Biotech	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Non-Current Assets	248.16	1,291.22	2,525.44	770.28	5,617.77
Current Assets	388.03	2,585.66	1,109.77	3,803.22	1,539.85
Total Assets	647.94	4,037.51	3,705.61	4,921.88	7,246.72
Total Debt*	108.89	0.57	657.97	2.50	2,309.68
Net Current Assets	179.25	2,199.72	261.71	3,175.74	-537.25
Contingent Liabilities	1.63	17.53	160.01	370.49	51.57

	Fermenta Biotech	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Cash From Operating Activities	92.83	523.24	342.18	967.57	537.99
Cash Flow from Investing Activities	-43.00	-582.30	-325.92	-561.67	-369.46
Cash from Financing Activities	-42.29	-46.46	13.62	-798.31	-313.53
Net Cash Inflow / Outflow	7.55	-105.52	29.88	-392.41	-145.00

	Fermenta Biotech	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
ROCE (%)	21.99	24.97	11.43	23.39	14.47
ROE (%)	13.91	19.73	11.15	19.16	18.75
ROA (%)	9.22	18.69	7.80	14.95	9.26
EBIT Margin (%)	13.42	31.41	20.95	34.40	26.58
Net Margin (%)	11.00	28.10	16.19	26.88	20.60
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Fermenta Biotech	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Revenue Growth (%)	-3.15	15.01	27.91	10.69	9.59
EBIT Growth (%)	-39.49	18.45	58.32	24.14	16.84
Net Profit Growth (%)	-44.02	19.61	149.56	-9.09	62.68
EPS Growth (%)	-46.96	17.73	-3.57	14.40	67.41
Book Value Growth (%)	11.21	26.75	9.67	-0.34	36.71

	Fermenta Biotech	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Price / Earnings	25.34	32.59	71.40	23.53	25.96
Price / Book Value	3.40	5.90	7.45	4.12	4.25
Dividend Yield (%)	0.79	0.28	0.06	1.89	0.00
EV/EBITDA	16.42	25.96	43.10	15.98	17.02
Market Cap (₹ Cr)	914.72	11,439.22	6,819.66	21,592.90	17,980.08

	Fermenta Biotech	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Debt to Equity	0.02	0.00	0.07	0.00	0.24
Short term debt to equity ratio	0.23	0.00	0.16	0.00	0.12
Current Ratio	1.86	6.70	1.31	6.06	0.74
Quick Ratio	1.13	5.59	0.88	5.31	0.53
Interest Coverage	8.52	959.59	7.14	130.11	4.45

	Fermenta Biotech	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Debtors to sales (%)	21.84	36.10	30.84	7.07	21.07
Asset Turnover	0.81	0.63	0.48	0.52	0.45
Receivable days	71.83	121.68	113.81	26.06	63.88
Inventory Days	95.93	63.83	84.76	65.95	43.27
Payable days	147.04	108.28	101.94	81.01	151.85
Cash Conversion Cycle	20.73	77.23	96.62	11.00	-44.70

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.